FibroGen Inc. (NASDAQ: FGEN) is -6.71% lower on its value in year-to-date trading and has touched a low of $22.65 and a high of $51.56 in the current 52-week trading range. The FGEN stock was last observed hovering at around $43.97 in the last trading session, with the day’s loss setting it -3.96% off its average median price target of $70.00 for the next 12 months. It is also 56.03% off the consensus price target high of $91.00 offered by 9 analysts, but current levels are 9.07% higher than the price target low of $44.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $40.01, the stock is -3.79% and -5.53% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.43 million and changing -9.01% at the moment leaves the stock 0.09% off its SMA200. FGEN registered -11.68% loss for a year compared to 6-month loss of -6.54%. The firm has a 50-day simple moving average (SMA 50) of $41.49 and a 200-day simple moving average (SMA200) of $42.27.
The stock witnessed a -1.86% gain in the last 1 month and extending the period to 3 months gives it a -8.74%, and is -8.88% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.39% over the week and 4.81% over the month.
FibroGen Inc. (FGEN) has around 531 employees, a market worth around $3.66B and $119.30M in sales. Distance from 52-week low is 76.64% and -22.40% from its 52-week high. The company has generated returns on investments over the last 12 months (-15.30%).
FibroGen Inc. (FGEN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for FibroGen Inc. (FGEN) is a “Overweight”. 9 analysts offering their recommendations for the stock have an average rating of 2.20, where 4 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
FibroGen Inc. is expected to release its quarterly report on 03/03/2021 and quarterly earnings per share for the current quarter are estimated at -$0.14 with sales reaching $111.62M over the same period.The EPS is expected to grow by 13.60% this year, but quarterly earnings will post -15.50% year-over-year. Quarterly sales are estimated to grow 1,299.80% in year-over-year returns.
FibroGen Inc. (FGEN) Top Institutional Holders
300 institutions hold shares in FibroGen Inc. (FGEN), with 7.36M shares held by insiders accounting for 8.09% while institutional investors hold 83.60% of the company’s shares. The shares outstanding are 90.56M, and float is at 83.47M with Short Float at 9.91%. Institutions hold 76.84% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 7.53 million shares valued at $309.76 million. The investor’s holdings represent 8.28% of the FGEN Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 7.37 million shares valued at $303.02 million to account for 8.10% of the shares outstanding. The other top investors are Primecap Management Company which holds 7.08 million shares representing 7.78% and valued at over $291.3 million, while FMR, LLC holds 7.26% of the shares totaling 6.6 million with a market value of $271.55 million.
FibroGen Inc. (FGEN) Insider Activity
The most recent transaction is an insider sale by Yu K Peony, the company’s Chief Medical Officer. SEC filings show that Yu K Peony sold 3,350 shares of the company’s common stock on Dec 16 at a price of $41.61 per share for a total of $0.14 million. Following the sale, the insider now owns 0.19 million shares.
FibroGen Inc. disclosed in a document filed with the SEC on Dec 15 that Cotroneo Pat (SVP, Finance and CFO) sold a total of 3,068 shares of the company’s common stock. The trade occurred on Dec 15 and was made at $43.60 per share for $0.13 million. Following the transaction, the insider now directly holds 0.27 million shares of the FGEN stock.
Still, SEC filings show that on Sep 16, Yu K Peony (Chief Medical Officer) disposed off 3,351 shares at an average price of $44.01 for $0.15 million. The insider now directly holds 198,934 shares of FibroGen Inc. (FGEN).
FibroGen Inc. (FGEN): Who are the competitors?
The company’s main competitors (and peers) include Harvard Bioscience Inc. (HBIO) that is trading 52.80% up over the past 12 months. Illumina Inc. (ILMN) is 9.84% up on the 1-year trading charts. Short interest in the company’s stock has risen 2.66% from the last report on Oct 29, 2020 to stand at a total of 8.06 million short shares sold with a short interest ratio of 13.09.